| __timestamp | CRISPR Therapeutics AG | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 117418000 |
| Thursday, January 1, 2015 | 12573000 | 102526000 |
| Friday, January 1, 2016 | 42238000 | 105386000 |
| Sunday, January 1, 2017 | 69800000 | 110188000 |
| Monday, January 1, 2018 | 113773000 | 121544000 |
| Tuesday, January 1, 2019 | 179362000 | 127930000 |
| Wednesday, January 1, 2020 | 269407000 | 148917000 |
| Friday, January 1, 2021 | 17953000 | 440760000 |
| Saturday, January 1, 2022 | 110250000 | 540517000 |
| Sunday, January 1, 2023 | 130250000 | 435577000 |
| Monday, January 1, 2024 | -2314000 |
Unleashing insights
In the evolving landscape of biotechnology and pharmaceuticals, understanding cost structures is crucial. Jazz Pharmaceuticals plc and CRISPR Therapeutics AG, two industry leaders, have shown distinct trends in their cost of revenue from 2014 to 2023. Jazz Pharmaceuticals, with a consistent upward trajectory, peaked in 2022 with a cost of revenue approximately 4.6 times higher than its 2014 figure. This reflects their expanding operations and product portfolio. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, experienced a more volatile pattern. Their cost of revenue surged by over 17,000% from 2014 to 2020, highlighting rapid growth and investment in cutting-edge technologies. However, a notable dip in 2021 suggests strategic adjustments or operational efficiencies. These insights underscore the dynamic nature of the biotech sector, where innovation and cost management are key to sustaining growth.
Analyzing Cost of Revenue: AstraZeneca PLC and Jazz Pharmaceuticals plc
Cost Insights: Breaking Down AstraZeneca PLC and CRISPR Therapeutics AG's Expenses
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Expenses
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Walgreens Boots Alliance, Inc. vs Jazz Pharmaceuticals plc
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Geron Corporation
Jazz Pharmaceuticals plc vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: CRISPR Therapeutics AG vs Mesoblast Limited